By applying both single-cell proteomics and transcriptomics, their results confirmed that transient activation of CD14+HLA-DRhighCD11chigh (HLA-DRAhighCD83high) monocytes could be noted only in mild or moderate COVID-19 patients at early timepoint, while HLA-DRlowS100Ahigh monocytes was demonstrated to dominate in severe cases at late phase [24]. This evidence concerns the gene CD14 and COVID-19.